US FDA Calls For Clinical Trial Diversity Plan ‘As Soon As Practicable’ In Product Development
Executive Summary
Draft guidance outlines Race and Diversity Plan that would reify some of FDA’s efforts to increase racial and ethnic diversity in clinical trials with a mechanism that is applicable from IND through approval.
You may also be interested in...
Could The US FDA Set Clinical Trial Diversity Minimums?
Oncology Center of Excellence Director Richard Pazdur asked whether the FDA should have more conversations with sponsors about site selection and percentages of US participants.
Clinical Trial Diversity: User Fee Bill Wants FDA’s Assessment Of Whether It Needs More Authority
HHS is to evaluate the need for FDA authority to mandate postapproval studies or postmarket surveillance if sponsors do not meet diversity enrollment goals. By contrast, the DEPICT Act would have given the agency the authority to do so.
‘Diseases Don’t Discriminate’: CISCRP Hopes To Improve Trial Diversity With Targeted Messaging
The Center for Information & Study on Clinical Research Participation partnered with drug makers to bring trial awareness to diverse communities and also to help along companies’ own diversity efforts.